Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML

INTRODUCTION: Barasertib is the pro-drug of barasertib-hQPA, a selective Aurora B kinase inhibitor that has demonstrated preliminary anti-acute myeloid leukemia (AML) activity in the clinical setting. METHODS: This Phase I dose-escalation study evaluated the safety and tolerability of barasertib, co...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kantarjian, Hagop M, Sekeres, Mikkael A, Ribrag, Vincent, Rousselot, Philippe, Garcia-Manero, Guillermo, Jabbour, Elias J, Owen, Kate, Stockman, Paul K, Oliver, Stuart D
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3775947/
https://ncbi.nlm.nih.gov/pubmed/23763917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.03.019
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items